Postoperative outcomes of drug-eluting sinus implants versus oral methylprednisolone after functional endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps
Frontiers in Pharmacology · 19.11.2026 · 17
DOI: 10.3389/fphar.2026.1777466 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.11.2026. Verfasst von Jian-Miao Fang und 4 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug-eluting sinus implants provide sustained local corticosteroid delivery after functional endoscopic sinus surgery (FESS), but comparative evidence relative to systemic corticosteroid therapy remains limited. This study aimed to compare postoperative outcomes between these strategies in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Methods
This retrospective cohort included 129 patients treated between January 2022 and December 2024. Patients were classified into the drug-eluting sinus implant group, which underwent FESS with drug-eluting sinus implants (n = 68), and the oral methylprednisolone group, which underwent FESS followed by a 15-day oral methylprednisolone taper (n = 61). Both groups received the same routine postoperative care. The primary outcome was longitudinal change in the Sino-Nasal Outcome Test-22 (SNOT-22) score through Month 12. Secondary outcomes included visual analog scale (VAS) symptom scores, endoscopic healing outcomes, postoperative complications, and steroid-related adverse events. Biomarker changes were exploratory outcomes.
Results
SNOT-22 scores improved in both groups. At Month 12, the model-based between-group difference in change was −11.86 points (95% confidence interval [CI], −14.82 to −8.90; Holm-adjusted P < 0.001), with a similar multivariable-adjusted estimate (−11.32 points; 95% CI, −14.61 to −8.04; P < 0.001). Improvements in all five VAS symptom domains were greater in the drug-eluting sinus implant group after multiplicity correction. Compared with the oral methylprednisolone group, the drug-eluting sinus implant group had lower adjusted odds of synechiae or adhesion at Month 3 (adjusted odds ratio [OR], 0.09; 95% CI, 0.02–0.43) and ostial stenosis or obstruction at Month 6 (adjusted OR, 0.20; 95% CI, 0.06–0.65). Steroid-related adverse events occurred in 2.9% of patients in the drug-eluting sinus implant group and 16.4% of those in the oral methylprednisolone group (P = 0.013). Most inflammatory and type 2 biomarkers showed greater reductions at Month 3 in the drug-eluting sinus implant group after false discovery rate correction.
Conclusion
Compared with oral methylprednisolone, drug-eluting sinus implants was associated with greater symptom improvement, more favorable postoperative healing outcomes, fewer steroid-related adverse events, and greater reductions in several inflammatory biomarkers. Prospective controlled studies are needed to confirm these associations.
Zitieren
APA
Fang, J., Lin, Z., Hu, B., Lu, Z., & Zhang, Z. (2026). Postoperative outcomes of drug-eluting sinus implants versus oral methylprednisolone after functional endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1777466
Vancouver
Fang J, Lin Z, Hu B, Lu Z, Zhang Z. Postoperative outcomes of drug-eluting sinus implants versus oral methylprednisolone after functional endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1777466
BibTeX
@article{Fang2026,
author = {Fang, Jian-Miao and Lin, Zhi-Hong and Hu, Bao-Hua and Lu, Zhong-Hua and Zhang, Zhe},
title = {Postoperative outcomes of drug-eluting sinus implants versus oral methylprednisolone after functional endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1777466}
}
EUVIMED